Objective: The chemokine CXCL12 interacting with the CXC receptor 4 (CXCR4) has been reported to play a role in the development and progression of bronchial asthma, but its mechanism of action is still unknown. The objective of this study was to assess the effect of the CXCL12 neutraligand chalcone 4 on the migration of dendritic cells (DCs) in a murine model of allergic airway inflammation. Methods: A 21-day ovalbumin (OVA)-induced allergic-airway TH2 inflammation model in BALB/c mice was used. Four groups were sensitized with OVA adsorbed on alum and challenged either with OVA or saline for 4 days. Mice were treated intranasally with chalcone 4 (300 nmol/kg body weight) or solvent 2 h before each OVA or saline challenge; 24 h after the last challenge, CD11c+F4/80 DCs were counted in the bronchoalveolar lavage. Jugular-nodose ganglion complex (JNC) sections were sampled, and for immunofluorescence staining, cryocut sections were prepared. MHC II+F4/80 DCs as well as calcitonin gene-related peptide (CGRP)- and substance P (SP)-positive neuronal cell bodies were analyzed. Results: In OVA-challenged mice, chalcone 4 caused a significantly decreased DC/neuron ratio in the JNC from 51.7% in solvent-treated to 32.6% in chalcone 4-treated mice. In parallel, chalcone 4 also decreased the DC population in BALF from 11.5 × 103 cells in solvent to 4.5 × 103 cells in chalcone 4-treated mice. By contrast, chalcone 4 had no effect on the expression of the neuropeptides CGRP and SP in JNC. Conclusion: This study reported the CXCL12 neutraligand chalcone 4 to affect DC infiltration into the airways and airway ganglia as well as to decrease airway eosinophilic inflammation and, therefore, validated CXCL12 as a new target in allergic disease models of asthma.

1.
Heck S, Nguyen J, Le DD, Bals R, Dinh QT: Pharmacological therapy of bronchial asthma: the role of biologicals. Int Arch Allergy Immunol 2016; 168: 241–252.
2.
Wenzel SE: Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716–725.
3.
Lambrecht BN, Hammad H: The immunology of asthma. Nat Immunol 2015; 16: 45–56.
4.
Gonzalo JA, Lloyd CM, Peled A, Delaney T, Coyle AJ, Gutierrez-Ramos JC: Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 alpha in the inflammatory component of allergic airway disease. J Immunol 2000; 165: 499–508.
5.
Chen H, Xu X, Teng J, Cheng S, Bunjhoo H, Cao Y, Liu J, Xie J, Wang C, Xu Y, Xiong W: CXCR4 inhibitor attenuates allergen-induced lung inflammation by down-regulating MMP-9 and ERK1/2. Int J Clin Exp Pathol 2015; 8: 6700–6707.
6.
Daubeuf F, Hachet-Haas M, Gizzi P, Gasparik V, Bonnet D, Utard V, Hibert M, Frossard N, Galzi JL: An antedrug of the CXCL12 neu­traligand blocks experimental allergic asthma without systemic effect in mice. J Biol Chem 2013; 288: 11865–11876.
7.
Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ: AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol 2002; 160: 1353–1360.
8.
Sozzani S, Vermi W, Del PA, Facchetti F: Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol 2010; 31: 270–277.
9.
Lambrecht BN, Hammad H: Dendritic cell and epithelial cell interactions at the origin of murine asthma. Ann Am Thorac Soc 2014; 11(suppl 5):S236–S243.
10.
Tschernig T, Hartwig C, Jeron A, Dinh QT, Gereke M, Bruder D: First genomic analysis of dendritic cells from lung and draining lymph nodes in murine asthma. Int J Geno­mics 2015; 2015: 638032.
11.
Le DD, Rochlitzer S, Fischer A, Heck S, Tschernig T, Sester M, Bals R, Welte T, Braun A, Dinh QT: Allergic airway inflammation induces the migration of dendritic cells into airway sensory ganglia. Respir Res 2014; 15: 73.
12.
Le DD, Funck U, Wronski S, Heck S, Tschernig T, Bischoff M, Sester M, Herr C, Bals R, Welte T, Braun A, Dinh QT: Steroid treatment reduces allergic airway inflammation and does not alter the increased numbers of dendritic cells and calcitonin gene-related peptide-expressing neurons in airway sensory ganglia. Neuroimmunomodulation 2016; 23: 18–26.
13.
Kabashima K, Shiraishi N, Sugita K, Mori T, Onoue A, Kobayashi M, Sakabe J, Yoshiki R, Tamamura H, Fujii N, Inaba K, Tokura Y: CXCL12-CXCR4 engagement is required for migration of cutaneous dendritic cells. Am J Pathol 2007; 171: 1249–1257.
14.
Gasparik V, Daubeuf F, Hachet-Haas M, Rohmer F, Gizzi P, Haiech J, Galzi JL, Hibert M, Bonnet D, Frossard N: Prodrugs of a CXC chemokine-12 (CXCL12) neutraligand prevent inflammatory reactions in an asthma model in vivo. ACS Med Chem Lett 2012; 3: 10–14.
15.
Hachet-Haas M, Balabanian K, Rohmer F, Pons F, Franchet C, Lecat S, Chow KY, Dagher R, Gizzi P, Didier B, Lagane B, Kellenberger E, Bonnet D, Baleux F, Haiech J, Parmentier M, Frossard N, Arenzana-Seisdedos F, Hibert M, Galzi JL: Small neutralizing molecules to inhibit actions of the chemokine CXCL12. J Biol Chem 2008; 283: 23189–23199.
16.
Daubeuf F, Frossard N: Acute asthma models to ovalbumin in the mouse. Curr Protoc Mouse Biol 2013; 3: 31–37.
17.
Dinh QT, Mingomataj E, Quarcoo D, Groneberg DA, Witt C, Klapp BF, Braun A, Fischer A: Allergic airway inflammation induces tachykinin peptides expression in vagal sensory neurons innervating mouse airways. Clin Exp Allergy 2005; 35: 820–825.
18.
Daubeuf F, Frossard N: Performing bronchoalveolar lavage in the mouse. Curr Protoc Mouse Biol 2012; 2: 167–175.
19.
Omlor AJ, Le DD, Schlicker J, Hannig M, Ewen R, Heck S, Herr C, Kraegeloh A, Hein C, Kautenburger R, Kickelbick G, Bals R, Nguyen J, Dinh QT: Local effects on airway inflammation and systemic uptake of 5 nm PEGylated and citrated gold nanoparticles in asthmatic mice. Small 2017; 13, DOI: 10.1002/smll.201603070.
20.
Veres TZ, Rochlitzer S, Shevchenko M, Fuchs B, Prenzler F, Nassenstein C, Fischer A, Wel­ker L, Holz O, Muller M, Krug N, Braun A: Spatial interactions between dendritic cells and sensory nerves in allergic airway inflammation. Am J Respir Cell Mol Biol 2007; 37: 553–561.
21.
Ishmael FT: The inflammatory response in the pathogenesis of asthma. J Am Osteopath Assoc 2011; 111:S11–S17.
22.
Barnes PJ: The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118: 3546–3556.
23.
Abboud D, Daubeuf F, Do QT, Utard V, Villa P, Haiech J, Bonnet D, Hibert M, Bernard P, Galzi JL, Frossard N: A strategy to discover decoy chemokine ligands with an anti-inflammatory activity. Sci Rep 2015; 5: 14746.
24.
Delgado-Martin C, Escribano C, Pablos JL, Riol-Blanco L, Rodriguez-Fernandez JL: Chemokine CXCL12 uses CXCR4 and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK)1/2, and mammalian target of rapamycin complex 1 (mTORC1) proteins to control chemotaxis and survival simultaneously in mature dendritic cells. J Biol Chem 2011; 286: 37222–37236.
25.
Sallusto F, Lanzavecchia A: Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J Exp Med 1999; 189: 611–614.
26.
Hintzen G, Ohl L, del Rio ML, Rodriguez-Barbosa JI, Pabst O, Kocks JR, Krege J, Hardtke S, Forster R: Induction of tolerance to innocuous inhaled antigen relies on a CCR7-dependent dendritic cell-mediated antigen transport to the bronchial lymph node. J Immunol 2006; 177: 7346–7354.
27.
Ohl L, Mohaupt M, Czeloth N, Hintzen G, Kiafard Z, Zwirner J, Blankenstein T, Henning G, Forster R: CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 2004; 21: 279–288.
28.
Forster R, Davalos-Misslitz AC, Rot A: CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008; 8: 362–371.
29.
Le DD, Schmit D, Heck S, Omlor AJ, Sester M, Herr C, Schick B, Daubeuf F, Fahndrich S, Bals R, Frossard N, Al KB, Dinh QT: Increase of mast cell-nerve association and neuropeptide receptor expression on mast cells in perennial allergic rhinitis. Neuroimmunomodulation 2016; 23: 261–270.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.